Attorney's Docket No. 9052-111

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Antson et al.

Examiner:

To be assigned

Serial No.:

10/088,245

Group Art Unit:

To be assigned

International Application No. PCT/GB00/03568

Filed: For:

September 18, 2000 (I.A. Filing Date)

TARGET FOR ANTIVIRAL THERAPY

Date: July 3, 2002

Box PCT

U.S. Patent and Trademark Office

Washington, D.C. 20231

## RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

Sir:

It is alleged that the above referenced application contains the following defect. "Additional claim fees of \$672 as a non-small entity, including any required multiple dependent claim fee are required." Applicants note that non-small entity status was never claimed. Additionally, applicants note that all multiple dependent claims were amended in the Preliminary Amendment. Form PTO-1390 includes the amount of \$1008.00 after multiple dependent claims, as this is the amount paid for the total independent claims not the \$924.00. Accordingly, applicants respectfully submit that there are no defects with the present application. Should there be any additional fee required, the Commissioner is hereby authorized to charge any additional fees required to Deposit Account No. 50-0220.

Respectfully submitted,

Járett K. Abramson

Registration No. 47,376

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 015809678 US

Date of Deposit: July 3, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: Box PCT, Commissioner for Patents, Washington, DG 20231, Attn: PO/EO/US.

Susan E. Freedman

Date of Signature: July 3, 2002

TTORNEY'S DOCKET NUMBER 9052-111
U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/088 245

1		PONCEDNING A EU INC UNIDED 25 U.S.C. 271	10/088,245						
CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIME									
PC7	r/GE	300/03568 18 September 2000	17 September 1999						
TITLE OF INVENTION TARGET FOR ANTIVIRAL THERAPY									
APPLICANT(S) FOR DO/EO/US									
ANTSON, Alfred; MAITLAND, Norman  Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:									
Applicant herewith submits to the Office States Designated Diction Office (DO/EO/OS) the following items and other information.									
1.		This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.							
2.	$\boxtimes$	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.							
3.	$\boxtimes$	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include							
		items (5), (6), (9) and (21) indicated below.							
4.		The US has been elected by the expiration of 19 months from the priority date (Article 31).							
5.		A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
		a.  is attached hereto (required only if not communicated by the International Bureau).							
		b.  has been communicated by the International Bureau.							
		c.  is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a. is attached hereto.							
		b. has been previously submitted under 35 U.S.C. 154(d)(4)							
7.		Amendments to the claims of the International Application Under PCT Article 19 (35 U.S.C. 371(c)(3))							
		a. are attached hereto (required only if not communicated by the International Bureau).							
		b.  have been communicated by the International Bureau.							
		c.  have not been made; however, the time limit for making such amendments has NOT expired.							
		d. have not been made and will not be made.							
8.		An English language translation of the amendments to the claims under PCT Art	ticle 19 (35 U.S.C. 371(c)(3)).						
9.	$\boxtimes$	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.		An English language translation of the annexes of the International Preliminary Examination Report Under PCT							
		Article 36 (35 U.S.C. 371(c)(5)).							
•	Items 11 to 20 below concern document(s) or information included:								
11.	$\boxtimes$	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12.		An assignment document for recording. A separate cover sheet in compliance w	rith 37 CFR 3.28 and 3.31 is included.						
13.		A FIRST preliminary amendment.							
14.		A SECOND or SUBSEQUENT preliminary amendment.							
15.		A substitute specification.							
16.		A change of power of attorney and/or address letter.							
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.							
18.	$\boxtimes$	A second copy of the published international application under 35 U.S.C. 154(d)(4).							
19.		A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4)							
20.	$\boxtimes$	Other items or information: RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)							

U.S. APPLICATION NO. (if kn 10/088,245	own, see 37 CFR 1.5) IN	ATTORNEY DOCKET NO. 9052-111							
21. A The following fee		CALCULATIONS	PTO USE ONLY						
nor international search fe	iminary examination fee (.ee (37 CFR 1.445(a)(2)) part (2) Report not prepared by the								
	examination fee (37 CFR Search Report prepared by								
	examination fee 37 CFR 1 ee (37 CFR 1.445(a)(2)) pa								
	examination fee (37 CFR sfy provisions of PCT Arti								
	examination fee (37 CFR rovisions of PCT Article 3	\$	F						
		APPROPRIATE BASE I							
	furnishing the oath or dec priority date (37 CFR 1.49	\$130.00							
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$					
Total claims	- 20 =		x \$18.00	\$					
Independent Claims	<b>-</b> 3 =		x \$84.00	\$					
MULTIPLE DEPEND	ENT CLAIM(S) (if app	licable)	+ \$280.00	\$					
	TOTAL	OF ABOVE CALC	ULATIONS =	\$					
Applicant claims sm reduced by 1/2	all entity status. See 37 C	FR 1.27. The fees indicate	ed above are	\$					
		S	SUBTOTAL =	\$					
Processing fee of \$130.00	for furnishing the English	h translation later than							
	claimed priority date (37 C	\$							
		\$							
	closed assignment (37 CFI								
accompanied by an appro	priate cover sheet (37 CF)	\$	<u> </u>						
. And and and American Community	e Tanadan — e edit edit e	TOTAL FEES I	ENCLOSED =	\$					
NOBOROW NEW YORK TO THE LAND OF THE LAND O				Amount to be refunded:	\$				
2 82 2 2004 00 02				charged:	\$130.00				
		o cover the above fees is e							
	Please charge my Deposit Account No. 50-0220 in the amount of \$130.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
	□ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220. A duplicate copy of this sheet is enclosed.								
d.  Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> information should not be included on this form. Provide credit card information and authorization on PTO-2038.									
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPO	NDENCE TO:								
207	<b>        </b> 92	Express M	Date: July 3, 2002  CERTIFICATE OF EXPRESS MAILING Express Mail Label No. EV 015809678 US						
PATENT TRADEM	-	rrespondence is being depo							

States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR
1.10 on the date indicated above and is addressed to: BOX PCT, Attn: DO/EO/US,
Commissioner for Patents Washington, DC 20231.

Susan E. Freedman